MaxCyte Inc.
07/01/2022 | Press release | Distributed by Public on 07/01/2022 00:09
Total Voting Rights
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
Gaithersburg, Maryland - 1 July 2022: MaxCyte (LSE: MXCT),a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that pursuant to its block admission facility, it has recently issued 87,177 of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options. The new Common Stock will rank pari passuwith the existing shares of common stock of the Company.
As of 30 June 2022,the total issued stock capital of the Company following the recent issue of the new Common Stock is 101,627,229 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.
For further information, please contact:
|
MaxCyte Contacts: US IR Adviser Gilmartin Group David Deuchler, CFA |
+1 415-937-5400 |
|||
|
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
|||
|
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh |
+44 (0)203 709 5700 |
|||
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.